Abstract:The exact pathogenesis of chronic obstructive pulmonary disease (COPD) remains largely unknown. While current management strategies are effective at stabilizing the disease or relief the symptoms, new approaches are required to target underlying disease process and reverse lung function deterioration. Recent research showed that pneumonia bacteria is critical in disease progression and gut microbiome is likely perturbed in COPD, which is usually accompanied by a decreased intestinal microbial diversity and a disturbance in immune system, contributing to a chronic inflammation. The cross-talk between gut microbes and lungs, termed as the “gut-lung axis,” is known to impact immune response and homeostasis in the airway. Although the gut and respiratory microbiota exhibit compositional differences, the gut and lung showed similarities in the origin of epithelia of both gastrointestinal and respiratory tracts, the anatomical structure, and early-life microbial colonization. Evidence showed that respiratory infection might be prevented, or at least dampened by regulating gut microbial ecosystem; thus, a promising yet understudied area of COPD management is nutrition-based preventive strategies. COPD patient is often deficient in nutrient such as antioxidant, vitamins, and fiber intake. However, further larger-scale randomized clinical trials (RCTs) are required to establish the role of these nutrition-based diet in COPD management. In this review, we highlight the important and complex interaction of microbiota and immune response on gut-lung axis. Further research into the modification and improvement of the gut microbiota and new interventions through diet, probiotics, vitamins, and fecal microbiota transplantation is extreme critical to provide new preventive therapies for COPD.

Gut microbiota: A new insight into lung diseases

Lung microbiome: new insights into the pathogenesis of respiratory diseases

A new perspective on gut-lung axis affected through resident microbiome and their implications on immune response in respiratory diseases

Lung microbiota and potential treatment of respiratory diseases

Respiratory diseases and gut microbiota: relevance, pathogenesis, and treatment

Lung microbiota: implications and interactions in chronic pulmonary diseases

COPD and Gut–Lung Axis: How Microbiota and Host Inflammasome Influence COPD and Related Therapeutics

Gut-Lung Microbiota in Chronic Pulmonary Diseases: Evolution, Pathogenesis, and Therapeutics

Role of Microbiota on Lung Homeostasis and Diseases

The Cross-Talk Between Gut Microbiota and Lungs in Common Lung Diseases

The human lung microbiome—A hidden link between microbes and human health and diseases

Emerging Cellular and Molecular Interactions Between the Lung Microbiota and Lung Diseases

Gut microbial metabolites in lung cancer development and immunotherapy: Novel insights into gut-lung axis

The role of gut-lung axis in COPD: Pathogenesis, immune response, and prospective treatment

Lung and Gut Affair

The Intriguing Connection Between the Gut and Lung Microbiomes

The Influence of the Gut Microbiota on Host Health: A Focus on the Gut–Lung Axis and Therapeutic Approaches

Bypassing the Gut–Lung Axis via Microbial Metabolites: Implications for Chronic Respiratory Diseases

Short-Chain Fatty Acid (SCFA) as a Connecting Link between Microbiota and Gut-Lung Axis—A Potential Therapeutic Intervention to Improve Lung Health

Targeting the Pulmonary Microbiota to Fight against Respiratory Diseases